204694-69-9

Upstream product

• 204693-53-8 1-[N²-(3,5-dibromo-D-tyrosyl)-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine 
• 349535-07-5 N-[(1,1-dimethylethoxy)carbonyl]-3,5-dibromo-D-tyrosine 
• 204692-58-0 1-[N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine 
• 204692-44-4 1-[N²-(1,1-dimethylethoxycarbonyl)-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine 
• 2389-45-9 Boc-Lys(Z)-OH 
• 1008-91-9 4-(piperazin-1-yl)pyridine 
• 204692-76-2 1-[N₂-[N-(1,1-dimethylethoxycarbonyl)-3,5-dibromo-D-tyrosyl]-N₆-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine 

Relevant academic research and scientific papers

Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N 2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl) -1-piperidinyl]carbonyl]-D-tyrosyl]-L-ly

Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings. Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans. Our novel

Modified amino acids, pharmaceuticals containing these compounds and method for their production

The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4 and R11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.